31.71 USD
+0.32 (+1.02%)
32.7977 USD
+1.09 (+3.43%)
Taking everything into account, GMAB scores 6 out of 10 in our fundamental rating. GMAB was compared to 534 industry peers in the Biotechnology industry. GMAB scores excellent points on both the profitability and health parts. This is a solid base for a good stock. GMAB has a correct valuation and a medium growth rate. This makes GMAB very considerable for quality investing!
1. Profitability
1.1 Basic Checks
GMAB had positive earnings in the past year.
In the past year GMAB had a positive cash flow from operations.
GMAB had positive earnings in each of the past 5 years.
Each year in the past 5 years GMAB had a positive operating cash flow.
1.2 Ratios
The Return On Assets of GMAB (21.10%) is better than 97.19% of its industry peers.
The Return On Equity of GMAB (25.76%) is better than 97.00% of its industry peers.
The Return On Invested Capital of GMAB (17.11%) is better than 96.63% of its industry peers.
The Average Return On Invested Capital over the past 3 years for GMAB is below the industry average of 18.60%.
The last Return On Invested Capital (17.11%) for GMAB is above the 3 year average (15.20%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 21.1% | ||
| ROE | 25.76% | ||
| ROIC | 17.11% |
ROA(3y)15.92%
ROA(5y)16.24%
ROE(3y)18.48%
ROE(5y)18.5%
ROIC(3y)15.2%
ROIC(5y)16.1%
1.3 Margins
GMAB has a better Profit Margin (41.35%) than 97.57% of its industry peers.
GMAB's Profit Margin has declined in the last couple of years.
GMAB's Operating Margin of 36.85% is amongst the best of the industry. GMAB outperforms 97.75% of its industry peers.
GMAB's Operating Margin has declined in the last couple of years.
GMAB has a Gross Margin of 94.27%. This is amongst the best in the industry. GMAB outperforms 94.01% of its industry peers.
GMAB's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 36.85% | ||
| PM (TTM) | 41.35% | ||
| GM | 94.27% |
OM growth 3Y-2.13%
OM growth 5Y-7.73%
PM growth 3Y1.23%
PM growth 5Y-2.03%
GM growth 3Y-1.55%
GM growth 5YN/A
2. Health
2.1 Basic Checks
GMAB has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for GMAB has been reduced compared to 1 year ago.
The number of shares outstanding for GMAB has been reduced compared to 5 years ago.
The debt/assets ratio for GMAB is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 11.71 indicates that GMAB is not in any danger for bankruptcy at the moment.
GMAB has a better Altman-Z score (11.71) than 83.90% of its industry peers.
GMAB has a debt to FCF ratio of 0.12. This is a very positive value and a sign of high solvency as it would only need 0.12 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.12, GMAB belongs to the top of the industry, outperforming 95.69% of the companies in the same industry.
GMAB has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of GMAB (0.02) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.12 | ||
| Altman-Z | 11.71 |
ROIC/WACC2.47
WACC6.94%
2.3 Liquidity
A Current Ratio of 6.03 indicates that GMAB has no problem at all paying its short term obligations.
The Current ratio of GMAB (6.03) is better than 64.04% of its industry peers.
GMAB has a Quick Ratio of 6.01. This indicates that GMAB is financially healthy and has no problem in meeting its short term obligations.
GMAB has a better Quick ratio (6.01) than 64.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.03 | ||
| Quick Ratio | 6.01 |
3. Growth
3.1 Past
GMAB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -34.66%.
Measured over the past 5 years, GMAB shows a small growth in Earnings Per Share. The EPS has been growing by 0.56% on average per year.
Looking at the last year, GMAB shows a very strong growth in Revenue. The Revenue has grown by 24.66%.
Measured over the past years, GMAB shows a very strong growth in Revenue. The Revenue has been growing by 31.16% on average per year.
EPS 1Y (TTM)-34.66%
EPS 3Y-8.61%
EPS 5Y0.56%
EPS Q2Q%121.44%
Revenue 1Y (TTM)24.66%
Revenue growth 3Y32.63%
Revenue growth 5Y31.16%
Sales Q2Q%-81.55%
3.2 Future
The Earnings Per Share is expected to decrease by -4.27% on average over the next years.
GMAB is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.32% yearly.
EPS Next Y-50.12%
EPS Next 2Y-24.94%
EPS Next 3Y-11.85%
EPS Next 5Y-4.27%
Revenue Next Year22.84%
Revenue Next 2Y19.35%
Revenue Next 3Y17.25%
Revenue Next 5Y13.32%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 13.44, the valuation of GMAB can be described as correct.
96.07% of the companies in the same industry are more expensive than GMAB, based on the Price/Earnings ratio.
GMAB's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.15.
GMAB is valuated correctly with a Price/Forward Earnings ratio of 16.07.
Compared to the rest of the industry, the Price/Forward Earnings ratio of GMAB indicates a rather cheap valuation: GMAB is cheaper than 95.32% of the companies listed in the same industry.
GMAB is valuated cheaply when we compare the Price/Forward Earnings ratio to 36.22, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.44 | ||
| Fwd PE | 16.07 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of GMAB indicates a rather cheap valuation: GMAB is cheaper than 96.63% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, GMAB is valued cheaply inside the industry as 95.69% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 16.23 | ||
| EV/EBITDA | 10.4 |
4.3 Compensation for Growth
GMAB has a very decent profitability rating, which may justify a higher PE ratio.
GMAB's earnings are expected to decrease with -11.85% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)23.99
EPS Next 2Y-24.94%
EPS Next 3Y-11.85%
5. Dividend
5.1 Amount
GMAB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
31.71
+0.32 (+1.02%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners38.32%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap19.53B
Revenue(TTM)3.58B
Net Income(TTM)1.48B
Analysts74.62
Price Target55.27 (74.3%)
Short Float %1.91%
Short Ratio4.93
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.75%
Min EPS beat(2)25.14%
Max EPS beat(2)36.36%
EPS beat(4)4
Avg EPS beat(4)61.45%
Min EPS beat(4)25.14%
Max EPS beat(4)134.67%
EPS beat(8)6
Avg EPS beat(8)30.72%
EPS beat(12)8
Avg EPS beat(12)16.62%
EPS beat(16)12
Avg EPS beat(16)28.7%
Revenue beat(2)1
Avg Revenue beat(2)-0.2%
Min Revenue beat(2)-1.49%
Max Revenue beat(2)1.09%
Revenue beat(4)2
Avg Revenue beat(4)-1.55%
Min Revenue beat(4)-7.66%
Max Revenue beat(4)1.87%
Revenue beat(8)6
Avg Revenue beat(8)146.79%
Revenue beat(12)9
Avg Revenue beat(12)91.3%
Revenue beat(16)9
Avg Revenue beat(16)47.26%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0.58%
EPS NQ rev (3m)5.61%
EPS NY rev (1m)3.93%
EPS NY rev (3m)5.39%
Revenue NQ rev (1m)-0.85%
Revenue NQ rev (3m)1.93%
Revenue NY rev (1m)0.54%
Revenue NY rev (3m)1.83%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.44 | ||
| Fwd PE | 16.07 | ||
| P/S | 5.45 | ||
| P/FCF | 16.23 | ||
| P/OCF | 15.32 | ||
| P/B | 3.4 | ||
| P/tB | 5.35 | ||
| EV/EBITDA | 10.4 |
EPS(TTM)2.36
EY7.44%
EPS(NY)1.97
Fwd EY6.22%
FCF(TTM)1.95
FCFY6.16%
OCF(TTM)2.07
OCFY6.53%
SpS5.82
BVpS9.34
TBVpS5.92
PEG (NY)N/A
PEG (5Y)23.99
Graham Number22.27
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 21.1% | ||
| ROE | 25.76% | ||
| ROCE | 21.02% | ||
| ROIC | 17.11% | ||
| ROICexc | 37.46% | ||
| ROICexgc | 140.29% | ||
| OM | 36.85% | ||
| PM (TTM) | 41.35% | ||
| GM | 94.27% | ||
| FCFM | 33.59% |
ROA(3y)15.92%
ROA(5y)16.24%
ROE(3y)18.48%
ROE(5y)18.5%
ROIC(3y)15.2%
ROIC(5y)16.1%
ROICexc(3y)68.77%
ROICexc(5y)79.83%
ROICexgc(3y)104.16%
ROICexgc(5y)104.49%
ROCE(3y)18.68%
ROCE(5y)19.78%
ROICexgc growth 3Y22.66%
ROICexgc growth 5Y11.4%
ROICexc growth 3Y-22.7%
ROICexc growth 5Y-14.09%
OM growth 3Y-2.13%
OM growth 5Y-7.73%
PM growth 3Y1.23%
PM growth 5Y-2.03%
GM growth 3Y-1.55%
GM growth 5YN/A
F-Score7
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.12 | ||
| Debt/EBITDA | 0.09 | ||
| Cap/Depr | 106.94% | ||
| Cap/Sales | 1.98% | ||
| Interest Coverage | 243.04 | ||
| Cash Conversion | 91.92% | ||
| Profit Quality | 81.24% | ||
| Current Ratio | 6.03 | ||
| Quick Ratio | 6.01 | ||
| Altman-Z | 11.71 |
F-Score7
WACC6.94%
ROIC/WACC2.47
Cap/Depr(3y)96.21%
Cap/Depr(5y)101.76%
Cap/Sales(3y)1.96%
Cap/Sales(5y)2.38%
Profit Quality(3y)107.36%
Profit Quality(5y)103.53%
High Growth Momentum
Growth
EPS 1Y (TTM)-34.66%
EPS 3Y-8.61%
EPS 5Y0.56%
EPS Q2Q%121.44%
EPS Next Y-50.12%
EPS Next 2Y-24.94%
EPS Next 3Y-11.85%
EPS Next 5Y-4.27%
Revenue 1Y (TTM)24.66%
Revenue growth 3Y32.63%
Revenue growth 5Y31.16%
Sales Q2Q%-81.55%
Revenue Next Year22.84%
Revenue Next 2Y19.35%
Revenue Next 3Y17.25%
Revenue Next 5Y13.32%
EBIT growth 1Y41.76%
EBIT growth 3Y29.8%
EBIT growth 5Y21.02%
EBIT Next Year50.35%
EBIT Next 3Y30.08%
EBIT Next 5Y18.11%
FCF growth 1Y46.62%
FCF growth 3Y51.06%
FCF growth 5Y42.84%
OCF growth 1Y44.68%
OCF growth 3Y47.08%
OCF growth 5Y41.48%
GENMAB A/S -SP ADR / GMAB FAQ
What is the ChartMill fundamental rating of GENMAB A/S -SP ADR (GMAB) stock?
ChartMill assigns a fundamental rating of 6 / 10 to GMAB.
What is the valuation status of GENMAB A/S -SP ADR (GMAB) stock?
ChartMill assigns a valuation rating of 6 / 10 to GENMAB A/S -SP ADR (GMAB). This can be considered as Fairly Valued.
Can you provide the profitability details for GENMAB A/S -SP ADR?
GENMAB A/S -SP ADR (GMAB) has a profitability rating of 7 / 10.
What is the valuation of GENMAB A/S -SP ADR based on its PE and PB ratios?
The Price/Earnings (PE) ratio for GENMAB A/S -SP ADR (GMAB) is 13.44 and the Price/Book (PB) ratio is 3.4.
What is the earnings growth outlook for GENMAB A/S -SP ADR?
The Earnings per Share (EPS) of GENMAB A/S -SP ADR (GMAB) is expected to decline by -50.12% in the next year.